News
Zacks Investment Research on MSN1d
Biogen Begins Phase III Felzartamab Study for Third Kidney DiseaseBiogen BIIB initiated dosing in a global, late-stage study of its investigational candidate, felzartamab, for treating adult patients with primary membranous nephropathy (PMN). Top-line data readout ...
StockStory.org on MSN6d
5 Revealing Analyst Questions From Biogen’s Q1 Earnings CallBiogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback